2024.11.06
THE LATEST PROGRESS IN THE FIM STUDY OF ···
Since the first implantation in November 2023, a total
of 9 patients have been enrolled in MonarQ™ ···
2024.11.05
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® ···
Two-year clinical data of the HighLife® TSMVR
technology's feasibility trial involving 30 cases···
2024.11.04
SmartWave LITHOTRIPSY VALVULOPLASTY TECH···
In the trial exploring the effectiveness and safety of
using the SmartWave lithotripsy valvuloplast···
2024.11.01
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF ···
At 2 years, the cardiac mortality rate was still lower
than the study’s prespecified performance go···
2024.10.31
INTERPRETATION OF PRE-MARKET CLINICAL DA···
During October 24-27, 2024, the pre-market
clinical data for the YonFlow® flow diverter was
offici···
2024.09.27
PROFESSOR WANG YAN'S TEAM AT XIAMEN UNIV···
On September 24, 2024, led by President Wang Yan
of Xiamen University Affiliated Cardiovascular
Ho···
2024.09.24
REGISTERED CLINICAL DATA OF TaurusElite®···
During September 20-22, 2024, Peijia presented multiple
clinical data at the PCR-CIT China Chengdu ···
2024.08.15
PEIJIA MEDICAL RECEIVES THE NMPA APPROVA···
Peijia Medical received the NMPA approval for the registration application of TaurusMax™ in August 1···
2024.06.13
HighLife® Transseptal Mitral Valve Repla···
From June 5 to 7, 2024, the New York Valves (NYV) conference was held, where Prof. Nicolo Piazza of ···
2024.06.13
MonarQ™ Transcatheter Tricuspid Valve Re···
From June 5 to 7, 2024, the latest results of the FIM clinical implantation of MonarQTM, an innovati···
2024.04.22
PEIJIA MEDICAL SHONE AT TWO MAJOR STRUC···
On March 18-24 and April 15-20, 2024, Peijia Medical shone at the 5th China Structural Heart Disease···
2024.04.19
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S···
On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by ···